{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-332742","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2026-08-04T20:03:07+00:00","discovered_at":"2026-08-04T20:04:00.992586+00:00","generated_at":"2026-08-04T20:05:00.145906+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Seres Therapeutics terminates Cambridge lease early, reduces facilities costs","bullets":["Surrenders 21,295 sq ft immediately; remaining 47,341 sq ft vacated by Dec 31, 2026 (original lease end Jan 13, 2031).","Total consideration: $2.2M LC increase, $3.85M termination fee, and 103,520 shares of stock valued at $500k.","Lease termination eliminates primary restoration obligations and reduces ongoing annual facilities costs.","Stock issued at $4.83 per share, registered on Form S-3, freely tradeable upon issuance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-332742","json":"https://secwatch.observer/filing/0001193125-26-332742.json","markdown":"https://secwatch.observer/filing/0001193125-26-332742.md","text":"https://secwatch.observer/filing/0001193125-26-332742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/0001193125-26-332742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526332742/d133274d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:05:00.145906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}